Comparative effectiveness in esophagogastric cancer

Area of Science:

• Oncology
• Surgical Oncology
• Gastroenterology

Background:

• Esophageal and gastroesophageal junction (GEJ) cancers have a poor prognosis, with increasing incidence in the US.
• Surgery alone has historically provided suboptimal long-term survival rates for these cancers.
• Systemic chemotherapy and radiation therapy have emerged as crucial treatment modalities.

Purpose of the Study:

• To review current evidence guiding treatment strategies for esophageal and GEJ cancers.
• To compare the efficacy of various treatment modalities, including neoadjuvant and adjuvant therapies.
• To discuss surgical management and adherence to national guidelines.

Main Methods:

• Review of existing evidence on chemotherapy and radiation therapy for esophageal, GEJ, and gastric cancers.
• Exploration of neoadjuvant (preoperative) and adjuvant (postoperative) treatment strategies.
• Analysis of surgical management, including lymph node dissection extent and guideline adherence.

Main Results:

• Neoadjuvant chemotherapy or chemoradiotherapy demonstrates superior outcomes compared to surgery alone for esophageal, GEJ, and gastric cancers.
• A trend towards improved survival is observed with neoadjuvant chemoradiotherapy versus chemotherapy alone.
• Adjuvant treatment is advised for patients with node-positive disease post-resection without prior neoadjuvant therapy.

Conclusions:

• Neoadjuvant chemoradiotherapy represents a preferred treatment approach for resectable esophageal and GEJ cancers.
• Adjuvant therapy plays a vital role in managing node-positive disease after surgical resection.
• Optimal management involves a multidisciplinary approach considering surgical extent and guideline adherence.